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S U M M A R Y
Objective: The aim of this study was to determine the distribution of serotypes and the antimicrobial
susceptibilities of Streptococcus pneumoniae clinical isolates causing invasive and non-invasive disease in
children aged 60 days in hospitals in Mexico.
Methods: A 15-year retrospective study was conducted for the period 2000 to 2014. Pneumococcal
clinical isolates were serotyped by Quellung reaction, and antimicrobial susceptibility testing was
performed with the broth microdilution method.
Results: A total of 126 pneumococcal isolates were collected. Pneumonia was the most frequent
diagnosis (40.5%), followed by meningitis (29.4%), septicemia (16.7%), and other clinical entities,
including otitis media and conjunctivitis (13.5%). The most frequent serotypes before the introduction of
heptavalent pneumococcal conjugate vaccine (PCV7) were 19F, 23F, 7F, and 35B. Serotypes 3, 6A, 10A,
12F, and 15A/B increased after the introduction of PCV7. Serotype 19A was isolated most frequently in
the pneumonia and meningitis cases only after the introduction of PCV7, and it displayed a high
resistance to penicillin.
Conclusions: Although the number of infections in infants aged 60 days was low, such infections were
not unusual events. New vaccination strategies should be evaluated to limit the risks in this age group.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus pneumoniae causes invasive (IPD) and non-
invasive (NIPD) pneumococcal disease, mainly in the pediatric
population and among the elderly. It is considered an uncommon
causative agent of neonatal sepsis, including serious infections
such as bacteremia, pneumonia, and meningitis; however, in
this age group and before the age of 2 months, such infections
can become fatal and have mortality rates that range from 1% to* Corresponding author. Tel.: +52 777 329 3046.
E-mail address: igechaniz@insp.mx (G. Echa´niz-Aviles).
1 Present address: Divisio´n de Excelencia Clı´nica. Coordinacio´n de Unidades
Me´dicas de Alta Especialidad. Instituto Mexicano del Seguro Social. Durango 291,
Mexico City.
http://dx.doi.org/10.1016/j.ijid.2015.12.001
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).14%.1–5 Reductions in the numbers of early-onset sepsis cases
caused by S. pneumoniae have been reported in the international
literature, including only a single case in Mexico,6 and the majority
of infections occur after 7 days of life.1 The mechanisms of
transmission of early and late infections are not entirely clear, but
vertical transmission (e.g., maternal bacteremia, chorioamnionitis,
prolonged membrane rupture, and cervico-vaginal colonization)
has been shown to predominate in early cases, whereas horizontal
transmission dominates in late cases, although these patterns are
not exclusive.1,6,7 Some neonatal conditions, such as preterm
delivery and low birth weight, as well as pneumococcal virulence
factors, can induce poor neonatal immune responses and increase
the risk of infection.4,8–10
In Mexico, immunization with the heptavalent pneumococcal
conjugate vaccine (PCV7) began in early 2006, when this vaccine wasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
A. Soto-Noguero´n et al. / International Journal of Infectious Diseases 42 (2016) 69–7370introduced gradually and only in the municipalities with the lowest
human development indices. In 2008, universal vaccination with
PCV7 was applied to the population aged under 1 year. During the
period from 2008 to 2010, PCV10 was introduced in a three-dose
schedule to the pediatric population insured by the Instituto
Mexicano del Seguro Social (IMSS), which covers half of the
population. Since 2011, PCV13 has been used in a 2-, 4-, and 12-
month schedule as part of the universal immunization program.11,12
The aim of this descriptive, retrospective study was to analyze the
distribution of serotypes and the antimicrobial susceptibilities of the
pneumococcal strains that caused invasive and non-invasive disease
in children aged less than 2 months during the 2000–2014 period.
2. Methods
2.1. Surveillance of S. pneumoniae and clinical samples
In 1993, Mexico entered the Sistema Regional de Vacunas
(SIREVA) project for Latin America,13 and since that time,
pneumococcal isolates from patients with invasive and non-
invasive disease from 23 participating hospitals have been sent
voluntarily, along with demographic data, to the Instituto Nacional
de Salud Pu´blica (INSP) in Cuernavaca, Morelos, Mexico. As part of
this passive laboratory surveillance, a retrospective study was
conducted for the period 2000 to 2014 with data from the SIREVA–
Mexico network, including S. pneumoniae isolates from unvacci-
nated infants younger than 2 months of age. Two sub-groups were
considered: newborns aged 0–7 days and infants aged 8–60 days.
Early-onset disease (EOD) cases were those that occurred within
the ﬁrst 7 days of life, and late-onset disease (LOD) cases were
those that occurred in patients between the ages of 8 and 60 days.
The analyses accounted for two periods: 2000–2007, before the
introduction of PCV7 (pre-PCV7); and 2008–2014, after the
introduction of PCV7 (post-PCV7).
2.2. Isolation and identiﬁcation
Invasive pneumococcal disease (IPD) was deﬁned by the
isolation of S. pneumoniae from blood, cerebrospinal ﬂuid (CSF),
and/or pleural ﬂuid. Bacteremic and/or complicated pneumonia
was deﬁned in the presence of a clinical diagnosis of
pneumonia and positive culture from blood and/or pleural ﬂuid.
Non-bacteremic pneumonia was considered when the treating
physician deﬁned an episode as pneumonia and the bronchial and/
or tracheal aspirates were positive for S. pneumoniae as a single
culture. Non-invasive pneumococcal disease (NIPD) included those
isolates from non-bacteremic pneumonia patients and isolatesTable 1
Demographic features and clinical diagnoses of infants with IPD and NIPD in Mexico
Age sub-group (days) 
Variable N (%) 0–7
(n = 25), n (%)
8–60
(n = 101)
Sex
Female 41 (32.5) 11 (44.0) 30 (29.7
Male 85 (67.5) 14 (56.0) 71 (70.3
Diagnosis
Meningitis 37 (29.4) 4 (22.2) 33 (64.7
Sepsis 21 (16.7) 10 (55.6) 11 (21.6
Bacteremic pneumonia 11 (8.7) 4 (22.2) 7 (13.7
IPD total 69 (54.7) 18 (72.0) 51 (50.5
Non-bacteremic pneumonia 40 (31.7) 3 (42.9) 37 (74.0
Other sites 17 (13.5) 4 (57.1) 13 (26.0
NIPD total 57 (45.2) 7 (28.0) 50 (49.5
Lethality 17 (13.5) 5 (20.0) 12 (11.9
IPD, invasive pneumococcal disease; NIPD, non-invasive pneumococcal disease; PCV, p
a Signiﬁcant p-values (0.05).from non-sterile sites, such as middle ear ﬂuid and eye discharge;
these sites were considered as ‘other sites’. The isolates were
identiﬁed by standard procedures that included tests for bile
solubility and optochin sensitivity. Pneumococcal isolates were
serotyped by the Quellung reaction with type- and factor-speciﬁc
antisera (Statens Serum Institut, Copenhagen, Denmark).
2.3. Antimicrobial susceptibility
Antimicrobial susceptibility tests for penicillin (PEN), cefotax-
ime (CTX), vancomycin (VAN), erythromycin (ERY), and chloram-
phenicol (CHL), all from Sigma-Aldrich USA, were performed by
broth microdilution method to determine the minimum inhibitory
concentration (MIC); the procedures of the Clinical and Laboratory
Standards Institute (CLSI) were followed, using cation-adjusted
Mueller–Hinton broth (CAMHB) supplemented with 3% lysed
horse blood. Interpretative criteria were differentiated for menin-
gitis and non-meningitis isolates according to CLSI guidelines; S.
pneumoniae ATCC 49619 was used as the control strain.14
2.4. Statistical analysis
Chi-square statistical analyses were performed using IBM SPSS
Statistics version 20.0 software (IBM Corp., Armonk, NY, USA); p-
values of 0.05 were interpreted as statistically signiﬁcant.
3. Results
A total of 1763 S. pneumoniae isolates from children younger
than 17 years of age with IPD and NIPD were collected during the
years 2000–2014. One hundred and twenty-six isolates (7.2%)
came from children 60 days of age. Twenty-ﬁve isolates (19.8%;
25/126) were obtained from newborns aged between 0 and 7 days
and 101 (80.2%; 101/126) from infants aged between 8 and
60 days. Males represented 67.5% (85/126) of the patients.
Meningitis was diagnosed in 29.4% (37/126) of the patients;
16.7% (21/126) had sepsis/bacteremia and 40.5% (51/126) had
pneumonia. Only 21.6% (11/51) of the isolates that caused
pneumonia came from blood cultures and/or pleural ﬂuid. Non-
bacteremic pneumonia was present in 78.4% (40/51) of the cases
and was signiﬁcantly more frequent in infants aged 8–60 days
(p = 0.0001). Other diseases, such as acute otitis media and
conjunctivitis, were diagnosed in 13.5% (17/126) of the cases.
IPD represented 54.8% (69/126) of the cases, whereas 45.2% (57/
126) corresponded to NIPD. There were 17 deaths, giving a
lethality rate of 13.5% (17/126) in both IPD and NIPD cases, as
shown in Table 1.Pre- and post-PCV7 era
, n (%)
p-Value 2000–2007
(n = 60), n (%)
2008–2014
(n = 66), n (%)
p-Value
) 22 (36.7) 19 (28.8)
) 38 (63.3) 47 (71.2)
) 0.0025a 17 (60.7) 20 (48.8)
) 0.0151a 6 (21.4) 15 (36.6)
) 5 (17.9) 6 (14.6)
) 28 (46.7) 41 (62.1)
) 0.0001a 22 (68.8) 18 (72.0)
) 10 (31.2) 7 (28.0)
) 32 (53.3) 25 (37.9)
) 3 (5.0) 14 (21.2) 0.0089a
neumococcal conjugate vaccine.
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vaccines, not including cross-reactive non-vaccine serotypes,
among children 60 days of age for the period 2000–2014 was
34.1% for PCV7, 46.8% for PCV10, 63.5% for PCV13, and 75.4% for the
23-valent pneumococcal polysaccharide vaccine (PPV23). During
the pre-PCV7 era, the theoretical vaccine serotype coverage for
PCV7 was 45%, and serotypes 23F and 19F were the most frequent
isolates. In the post-PCV7 years, an important reduction in PCV7
serotypes was observed (p = 0.0156), along with a signiﬁcant
increase in serotype 19A (p = 0.0007). Serotypes 3, 6A, 10A, 12F,
and 15A/B increased after the introduction of PCV7. Within the
study period, the non-vaccine serotypes corresponded to 36% of
the isolates. The majority of the pneumococcal serotypes in
children 7 days of age were included in any of the PCVs (Table 2).
Serotype 7F was frequently associated with meningitis primarily in
the post-PCV7 era. Pneumococcal serotypes 3, 19A, 19F (2), and
23F were the causes of death in children 7 days old, whereas
serotypes 6A, 7F (2), 10A, 11A, 12F, 14, 15A, 23F, 35B (2), and NT
(non-typeable) were the causes of death in the children aged 8–60
days. The lethality was higher in the post-PCV7 years, probably due
to the predominance of non-vaccine serotypes (i.e., 10A, 12F, 15A,
23A, and NT) (p = 0.03).
The results of the antimicrobial resistance tests are shown in
Figure 1. The serotypes isolated from patients with meningitis,
particularly in the post-PCV7 period, exhibited greater resistance
to penicillin, and a high proportion (28.8%) exhibited resistance to
erythromycin during the same period. Comparisons according to
age group and vaccination period revealed no signiﬁcant
differences. A signiﬁcant difference in the non-susceptibility
patterns of the IPD-causing strains was observed for penicillin
(p = 0.010). All strains were vancomycin-susceptible.Table 2
Serotype distribution of IPD and NIPD among the different age groups and vaccine per
Age sub-group (days) 
Serotypes N (%) 0–7
(n = 25), n (%)
8–60
(n = 101), 
Vaccine serotypes 80 (63.5) 19 (76.0) 61 (60.4
PCV serotypes
4 1 (0.8) 0 (0.0) 1 (1.0) 
6B 6 (4.7) 2 (8.0) 4 (4).0 
9V 3 (2.4) 0 (0.0) 3 (3.0) 
14 6 (4.7) 1 (4.0) 5 (5.0) 
18C 1 (0.8) 0 (0.0) 1 (1.0) 
19F 15 (11.9) 3 (12.0) 12 (11.9
23F 11 (8.7) 3 (12.0) 8 (7.9) 
PCV7 43 (34.1) 9 (36.0) 34 (33.7
1 6 (4.7) 2 (8.0) 4 (4.0) 
5 2 (1.6) 0 (0.0) 2 (2.0) 
7F 8 (6.3) 1 (4.0) 7 (6.9) 
PCV10 59 (46.8) 12 (48.0) 47 (46.5
3 5 (3.9) 4 (16.0) 1 (1.0) 
6A 5 (3.9) 1 (4.0) 4 (4.0) 
19A 11 (8.7) 2 (8.0) 9 (8.9) 
PCV13 80 (63.5) 19 (76.0) 61 (60.4
Non-PCV serotypes
35B 6 (4.7) 0 (0.0) 6 (5.9) 
11A 5 (3.9) 0 (0.0) 5 (5).0 
10A 4 (3.2) 2 (8.0) 2 (2.0) 
12F 3 (2.4) 0 (0.0) 3 (3.0) 
15A/B/C 8 (6.3) 3 (12.0) 5 (5.0) 
23A/B 5 (3.9) 0 (0.0) 5 (5.0) 
Non-typeable 5 (3.9) 1 (4.0) 4 (4.0) 
Otherb 10 (7.9) 0 (0.0) 10 (10.0
Total non-PCV serotypes 46 (36.5) 6 (24.0) 40 (39.6
Total 126 (100) 25 (19.8) 101 (80.2
IPD, invasive pneumococcal disease; NIPD, non-invasive pneumococcal disease; PCV, p
a Signiﬁcant p-values (0.05); only signiﬁcant p-values are shown.
b ‘Other’ includes the following serotypes: 2, 8, 13, 22F, 18A, 18F, 9A, 27, and 24F (n4. Discussion
In this 15-year study, the frequency of S. pneumoniae infection
cases in children less than 60 days of age was found to be relevant.
Some studies have found that S. pneumoniae is the causative agent
in approximately 1% to 11% of neonatal sepsis cases,1,15,16 and has
resulted in a high lethality rate even in the post-PCV7 period.3,17 In
the present study, 72% of the IPD cases occurred in children 7
days old, and sepsis was the predominant clinical diagnosis.
Although Streptococcus agalactiae (group B Streptococcus, GBS) is
conventionally regarded as one of the predominant pathogens of
early-onset neonatal infections, S. pneumoniae has also been
reported to be associated with infections in term and preterm
infants. Despite the similarities in the manifestations of neonatal
infections with GBS and S. pneumoniae, the latter is thought to be
more virulent.4,17
After the second week of age, the most common IPD was
meningitis. Half of the IPD cases occurred after the age of 7 days.
The mechanism of LOD may be related to colonization, which
occurs during passage through the maternal birth canal, or to the
acquisition of bacteria from older siblings and family members.
Regarding the IPD and NIPD cases, they were both more frequently
isolated in the 8–60-day-old group, as reported by Zaidi et al.2
Analysis of the isolated serotypes revealed clear but non-
signiﬁcant decreases in the frequencies of 23F and 19F serotypes
after the introduction of PCV7. However, despite the gradual
introduction of PCV13 starting in 2011, there was an increase in
serotype 19A, which was probably due to selection as a result of the
extensive use of antimicrobials and/or to suboptimal vaccine
coverage.18,19 Some authors have suggested that serotype 7F is a
frequent cause of IPD in children under 90 days of age.20,21 In theiods in Mexico
Pre- and post-PCV7 era
n (%)
p-Value 2000–2007
(n = 60), n (%)
2008–2014
(n = 66), n (%)
p-Value
) 38 (63.3) 42 (63.6)
1 (1.7) 0 (0.0)
2 (3.3) 4 (6.1)
1 (1.7) 2 (3.0)
4 (6.7) 2 (3.0)
0 (0.0) 1 (1.5)
) 11 (18.3) 4 (6.1)
8 (13.3) 3 (4.5)
) 27 (45.0) 16 (24.2) 0.0156a
3 (5.0) 3 (4.5)
1 (1.7) 1 (1.5)
5 (8.3) 3 (4.5)
) 36 (60.0) 23 (34.8) 0.0071a
0.0103a 1 (1.7) 4 (6.1)
1 (1.7) 4 (6.1)
0 (0.0) 11 (16.7) 0.0007a
) 38 (63.3) 42 (63.6)
5 (8.3) 1 (1.5)
4 (6.7) 1 (1.5)
1 (1.7) 3 (4.5)
0 (0.0) 3 (4.5)
2 (3.3) 6 (9.1)
2 (3.3) 3 (4.5)
1 (1.7) 4 (6.1)
) 7 (11.6) 3 (4.5)
) 22 (36.6) 24 (36.4)
) 60 (47.6) 66 (52.3)
neumococcal conjugate vaccine.
 = 1).
Figure 1. Antimicrobial resistance of the Streptococcus pneumoniae causing invasive pneumococcal disease (IPD) and non-invasive pneumococcal disease (NIPD) in children
60 days of age.
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observed; however, this serotype was most strongly associated
with meningitis. Serotypes 1 and 5 were not observed in the
present study, which is in contrast to a recent report from Uruguay
in which the majority of IPD cases in neonates were caused by
these serotypes.22 Differences in pneumococcal serotypes before
and after the introduction of PCV7 are limited by the small
numbers of isolates, particularly for those with p-values close to
signiﬁcance (0.05).
Although a trend towards a greater prevalence of LOD caused by
non-vaccine serotypes was observed, there were no statistically
signiﬁcant differences between the prevailing serotypes in the EOD
and LOD cases. During the surveillance program in Mexico, an
evident increase in non-vaccine serotypes in children below the
age of 5 years has been observed,23 due to an increase in serotype
19A and particularly in penicillin-resistant strains.24 It is important
to note that in infants aged 60 days, the proportions of infection
cases caused by PCV serotypes were similar before and after the
introduction of PCV; this effect is probably the result of the
mothers not being vaccinated, which would preclude the effect of
herd immunity due to PCV in this age group. In Mexico, it is unclear
whether current infant or adult pneumococcal immunization
programs might inﬂuence this incidence in the neonatal period.
Early-onset neonatal pneumococcal diseases are most likely
transmitted through the maternal vaginal tract. Maternal vaginal
colonization is rare but associated with a high risk of transmission
to the newborn.25 To protect the neonate from pneumococcal
diseases, the efﬁcacies of new vaccination strategies should be
explored. An earlier onset of vaccination (at 0, 10, and 14 weeks of
age) has been shown to induce speciﬁc protection against vaccine
serotypes.26,27 The increase in immunization coverage among
infants and the elderly with a concomitant decrease in nasopha-
ryngeal colonization suggests that a herd effect may protect the
newborn from early infection,28 and the vaccination of pregnant
women in the last trimester of pregnancy may reduce vertical
transmission29 and confer protective antibody levels against
speciﬁc vaccine serotypes27.
A study by Choudhury et al.30 revealed that when naturally
protective antibody levels were measured in different racial/ethnic
groups, only 8% of mothers and 2% of infants had antibody levels
4.4 mg/ml (this level predicts the spread of protective passive
immunity to newborns at 4 months of age). They found that 77% of
the Hispanic mothers tested were from Mexico, and among thisgroup, 53% of the mothers and 36% of the Hispanic infants had
protective antibody levels (0.35 mg/ml) for the serotypes tested.
Presumably, the levels of immunity observed in this population
may reﬂect the prevalent serotypes in Mexico and the ability of the
immune system to mount this level of immunity secondary to
environmental exposure in addition to natural infection, rather
than in response to vaccination. These ﬁndings could correlate
with the different S. pneumoniae serotypes that were identiﬁed in
infants aged 60 days in the present study.
Antimicrobial susceptibility of S. pneumoniae isolates was high
for all antibiotics both before and after the introduction of
PCV7, with the exception of penicillin in meningitis isolates. There
were no signiﬁcant differences according to age sub-group or
vaccination period, but a decrease in susceptibility to erythromy-
cin during the post-PCV7 period was observed. In a study
conducted in Israel by Ashkenazi et al.31 in 2012, in the same
age group, the authors reported an 87% susceptibility to penicillin;
13% of the strains exhibited intermediate susceptibility and none
of the strains was resistant. In contrast, a study by Imohl et al.32
conducted in Germany, reported a 3.1% resistance to penicillin in
cases of meningitis. In comparison, a decreased susceptibility and
an increased resistance only in terms of the meningitis isolates was
observed in the present study. Hsu et al. reported that non-vaccine
serotypes were generally more susceptible to antibiotics than
vaccine serotypes, with the exception of serotype 19A.33 The
empirical prescription of third-generation cephalosporins for the
treatment of neonatal sepsis and meningitis may decrease the risk
of treatment failure due to beta-lactam resistance.
This study illustrates the role of S. pneumoniae as a cause of
morbidity and mortality in infants aged 60 days, who continue to
be affected by vaccine and non-vaccine serotypes that cause
serious infections even after the introduction of PCV. This problem
may be the result of an unknown percentage of colonized mothers
and newborn susceptibility to early colonization with serotypes
circulating in the community, and is also suggestive of complex
interactions between infants, siblings, parents, and other house-
hold contacts.1 Due to the characteristics of the passive surveil-
lance system used in this study, it was not possible to analyze the
risk factors and other epidemiological characteristics of the cases.
Pneumococcal conjugate vaccines have been tested in new-
borns and proven to be safe,34 immunogenic, and not associated
with immunological tolerance in schedules at 0, 1, and 2 months,
or 0, 6, and 14 weeks of age.30 However, an insufﬁcient number of
A. Soto-Noguero´n et al. / International Journal of Infectious Diseases 42 (2016) 69–73 73studies assessing the impact on the population of the use of vaccine
in the newborn stage have been conducted. To further evaluate
public health interventions aimed at the immunological protection
of newborns, the acquisition of greater knowledge is needed. This
will allow for the rational design of vaccines or new vaccination
schedules for use in infants, reducing the morbidity and mortality
resulting from infection in the early stage of life, and the
implementation of effective prevention strategies.
Systematic vaccination is a measure that has elicited demon-
strable reductions in the incidence of IPD in children 2 months of
age. The frequency of IPD cases in children under 2 months of age
observed in this study and those reported in other countries,3,35
suggest that strategies for immunization to cover those children
whose ages are not included in the current scheme of immuniza-
tion with PCV should be assessed.
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